Daiichi Sankyo reportedly selling OTC unit for $900M in pivot to oncology — but company says it's 'incorrect'
Daiichi Sankyo has countered a news report that it’s looking to sell its over-the-counter subsidiary for about $900 million, once again dispelling speculation that’s been widely circulated as the drugmaker consolidates operations around its growing oncology unit.
Japanese publication Nikkei Business first reported that Daiichi Sankyo is in talks with several companies to sell Daiichi Sankyo Healthcare, which sells pain patches, cold medicines, nutritional supplements and the like. In March, unnamed sources told Reuters that the company had hired JP Morgan to advise on a potential deal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.